Filtered By:
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 30263 results found since Jan 2013.
Mistakes in managing hepatocellular carcinoma and how to avoid them: a narrative review
Expert Rev Gastroenterol Hepatol. 2023 Sep 7:1-7. doi: 10.1080/17474124.2023.2255515. Online ahead of print.ABSTRACTINTRODUCTION: Hepatocellular carcinoma (HCC) is the most common liver-related cancer and the third leading cause of worldwide cancer-related mortality.AREAS COVERED: There have been many updated guidelines on the management of HCC in the past few years. Given the increasing burden of HCC in clinical practice, knowledge of evidence-based standards of care for these patients is essential for any practitioner managing patients with HCC. Early detection and judicious treatment based on the stage of the HCC can im...
Source: Expert Review of Gastroenterology and Hepatology - September 6, 2023 Category: Gastroenterology Authors: Madunil Anuk Niriella Uditha Dassanayake H Janaka de Silva Source Type: research
The function of MSP-activated γδT cells in hepatocellular carcinoma
In conclusion, we demonstrated that the novel protein ligand MSP activated γδT cells, leading to the killing of HCC cells through direct and indirect mechanisms. These findings could provide a potential new target for the clinical diagnosis and treatment of HCC and a foundation for clinical treatment strategies in HCC.PMID:37669598 | DOI:10.1016/j.intimp.2023.110893
Source: International Immunopharmacology - September 5, 2023 Category: Allergy & Immunology Authors: Boyu Du Ruihong Yu Xiaoqing Geng Yulin Li Yirui Liu Shuaitong Liu Fangzhou Li QingQing Yu Yang Guo Xueyan Xi Source Type: research
Aberrant expression of cuproptosis ‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma
CONCLUSIONS: Upregulation of LIPT1 is involved in metabolic dysregulation of fatty acid and poor prognosis of HCC patients, which suggests that LIPT1 plays an important role in reprogramming lipid metabolism and could act as a potential prognostic marker and therapeutic target for HCC.PMID:37668796 | DOI:10.1007/s00432-023-05325-6
Source: Cell Research - September 5, 2023 Category: Cytology Authors: Jinping Li Dayun Tuo Gunan Guo Jinfeng Gan Source Type: research
Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma
World J Gastroenterol. 2023 Aug 21;29(31):4706-4735. doi: 10.3748/wjg.v29.i31.4706.ABSTRACTHepatocellular carcinoma (HCC) is a malignancy with a high incidence and fatality rate worldwide. Hepatitis B virus (HBV) infection is one of the most important risk factors for its occurrence and development. Early detection of HBV-associated HCC (HBV-HCC) can improve clinical decision-making and patient outcomes. Biomarkers are extremely helpful, not only for early diagnosis, but also for the development of therapeutics. MicroRNAs (miRNAs), a subset of non-coding RNAs approximately 22 nucleotides in length, have increasingly attrac...
Source: World Journal of Gastroenterology - September 4, 2023 Category: Gastroenterology Authors: Ming-He Zhang Yu-Feng Yuan Li-Juan Liu Yu-Xin Wei Wan-Yue Yin Lan-Zhuo-Yin Zheng Ying-Ying Tang Zhao Lv Fan Zhu Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
Objective response and progression free survival contribute to prolong overall survival in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma
CONCLUSION: The presence of anti-tumor response with tumor shrinkage during Atez/Bev treatment contributes to good OS through its durable response. Atez/Bev treatment could be considered as first-line treatment for unresectable HCC. However, there is a need for optimal biomarkers for good-anti-tumor response.PMID:37666216 | DOI:10.1159/000533952
Source: Oncology - September 4, 2023 Category: Cancer & Oncology Authors: Kazuto Tajiri Kenichiro Tsukada Yoshiharu Tokimitsu Yuchi Motofuji Kengo Kawai Nozomu Muraishi Aiko Murayama Yuka Hayashi Yukihiro Shimizu Ichiro Yasuda Source Type: research
A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations
CONCLUSION: The combined model incorporating clinicopathologic and MRI features demonstrated a satisfactory prediction result for LR-M HCC.PMID:37665140 | DOI:10.4274/dir.2023.232215
Source: Diagnostic and Interventional Radiology : The Turkish Society of Radiology - September 4, 2023 Category: Radiology Authors: Xin-Xing Hu Dong Bai Zhen-Lei Wang Yi Zhang Jue Zhao Mei-Ling Li Jia Yang Lei Zhang Source Type: research
Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study
CONCLUSION: The combination therapy provided significantly longer upfront LTP-free survival in HCCs >3 cm when compared with the MWA treatment alone, albeit with similar local tumor control and overall survival rates when accounting for additional locoregional therapies.PMID:37665139 | DOI:10.4274/dir.2023.232159
Source: Diagnostic and Interventional Radiology : The Turkish Society of Radiology - September 4, 2023 Category: Radiology Authors: Jason Chiang Pradeep S Rajendran Frank Hao James Sayre Steven S Raman David S K Lu Justin P McWilliams Source Type: research
A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations
CONCLUSION: The combined model incorporating clinicopathologic and MRI features demonstrated a satisfactory prediction result for LR-M HCC.PMID:37665140 | DOI:10.4274/dir.2023.232215
Source: Diagnostic and Interventional Radiology - September 4, 2023 Category: Radiology Authors: Xin-Xing Hu Dong Bai Zhen-Lei Wang Yi Zhang Jue Zhao Mei-Ling Li Jia Yang Lei Zhang Source Type: research
Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study
CONCLUSION: The combination therapy provided significantly longer upfront LTP-free survival in HCCs >3 cm when compared with the MWA treatment alone, albeit with similar local tumor control and overall survival rates when accounting for additional locoregional therapies.PMID:37665139 | DOI:10.4274/dir.2023.232159
Source: Diagnostic and Interventional Radiology - September 4, 2023 Category: Radiology Authors: Jason Chiang Pradeep S Rajendran Frank Hao James Sayre Steven S Raman David S K Lu Justin P McWilliams Source Type: research
Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma
World J Gastroenterol. 2023 Aug 21;29(31):4706-4735. doi: 10.3748/wjg.v29.i31.4706.ABSTRACTHepatocellular carcinoma (HCC) is a malignancy with a high incidence and fatality rate worldwide. Hepatitis B virus (HBV) infection is one of the most important risk factors for its occurrence and development. Early detection of HBV-associated HCC (HBV-HCC) can improve clinical decision-making and patient outcomes. Biomarkers are extremely helpful, not only for early diagnosis, but also for the development of therapeutics. MicroRNAs (miRNAs), a subset of non-coding RNAs approximately 22 nucleotides in length, have increasingly attrac...
Source: World Journal of Gastroenterology : WJG - September 4, 2023 Category: Gastroenterology Authors: Ming-He Zhang Yu-Feng Yuan Li-Juan Liu Yu-Xin Wei Wan-Yue Yin Lan-Zhuo-Yin Zheng Ying-Ying Tang Zhao Lv Fan Zhu Source Type: research
Two new 2-arylbenzo < em > b < /em > furans from < em > Itea indochinensis < /em > and their anti-hepatocellular carcinoma and anti-oxidant effects
Nat Prod Res. 2023 Sep 4:1-9. doi: 10.1080/14786419.2023.2252975. Online ahead of print.ABSTRACTTwo new 2-arylbenzo[b]furans (1-2) and ten known compounds (3-12) were identified from the 95% EtOH extract of the branches and leaves of Itea indochinensis for the first time. Their structures were determined mainly based on extensive analyses of UV, IR, 1D/2D NMR and HRMS spectra. The results of MTT assays demonstrated the anti-tumor potential of compound 1 with good selectivity, which displayed moderate inhibitory effects on proliferation of SK-hep-1 cells with IC50 value of 22.3 μM, while weak inhibitory effect on prolifera...
Source: Natural Product Research - September 4, 2023 Category: Biochemistry Authors: Fang-Fang Xu Jin-Zhen Jian Yi-Jv Li Zhi-Wei Wang Guo-Yong Luo Wu-De Yang Source Type: research
Gamma-glutamyl transferase levels in the prediction of the outcomes of hepatocellular carcinoma after surgical resection
J Formos Med Assoc. 2023 Sep 1:S0929-6646(23)00341-8. doi: 10.1016/j.jfma.2023.08.026. Online ahead of print.NO ABSTRACTPMID:37661528 | DOI:10.1016/j.jfma.2023.08.026
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Tung-Hung Su Jia-Horng Kao Source Type: research
